• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Bausch Health Companies Inc (NY: BHC )

    8.085 +0.045 (+0.56%)
    Streaming Delayed Price Updated: 10:24 AM EDT, Oct 28, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Bausch Health Companies Inc

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    11 12 Next >
    ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
    Via ACCESSWIRE
    Deal Dispatch: UFC, WWE Parent TKO Takes On Bull Riding; Endeavor Looks To Sell Tennis; Another Car Company Goes Bankrupt
    IMG tennis assets are on the auction block. The announcement came after TKO inked a deal with Endeavor for Professional Bull Riders. 
    Via Benzinga
    Deal Dispatch: Altus Power, Motorsport Games Explore Options, True Value Goes Bankrupt, M&A Activity Lags
    S&P Global's Joe Mantone puts the latest M&A data in perspective and how deal pros might react post-Election Day. 
    Via Benzinga
    Topics Bankruptcy Stocks
    Exposures Financial Legal US Equities
    Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
    Private equity giants TPG and Blackstone are pursuing a potential $14 billion buyout of Bausch + Lomb. 
    Via Benzinga
    Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners
    Via ACCESSWIRE
    Bausch Health Announces Second Quarter 2024 Results
    Via ACCESSWIRE
    Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
    The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting. 
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Bausch Health Responds to Market Rumors
    Via ACCESSWIRE
    Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024
    Via ACCESSWIRE
    Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises
    Via ACCESSWIRE
    Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value
    The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden. 
    Via MarketBeat
    Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
    Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week. 
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Contact Lens Supplier Bausch + Lomb Eyes Sale Amid Separation Challenges As Parent Bausch Health Faces Debt Issues
    Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a spin-off. 
    Via Benzinga
    Topics Supply Chain
    Exposures Supply Chain
    Bausch Health Welcomes Two New Members to the Executive Leadership Team
    Via ACCESSWIRE
    Bausch Health Announces 2024 Annual Meeting of Shareholder Results
    Via ACCESSWIRE
    Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?
    Bausch + Lomb is reportedly considering a sale. But its potential acquirers could come up against antitrust concerns. 
    Via Investor's Business Daily
    Bank Of Canada Cuts Rates Again As Inflation, Labor Market Cool: Canadian Stocks Rebound, Loonie Strengthens
    Bank of Canada cuts key policy rate by 25 basis points to 4.25% and suggests further cuts if inflation continues to ease. 
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Bausch Health Solvency Remains A Concerns, Analyst Downgrades Stock
    Bausch Health reports Q2 2024 GAAP EPS of $0.03, missing the consensus of $0.28. Revenue hits $2.403 billion, up 11% YoY. Piper Sandler downgrades BHC to Underweight with a price target of $3, citing... 
    Via Benzinga
    BHC Stock Plunges as Bausch Health Appears on the Brink of Bankruptcy
    Although Bausch Health has denied rumors that it’s on the cusp of bankruptcy, BHC stock is nevertheless suffering from skepticism. 
    Via InvestorPlace
    Topics Bankruptcy
    Exposures Financial Legal
    Why Bausch health Shares Are Falling Today
    Bausch Health Companies Inc. (NYSE: BHC) is experiencing a sharp decline in its stock price Wednesday. The drop was triggered by a report suggesting the company is negotiating a potential prepackaged... 
    Via Benzinga
    Topics Bankruptcy
    Exposures Financial Legal
    US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
    Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market... 
    Via Benzinga
    Stocks Plummet After Tech Earnings, Manufacturing Data
    The Dow Jones Industrial Average is down triple digits, while the S&P 500 Index eyes its worst daily percentage drop since September 2023. 
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
    After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a... 
    Via Benzinga
    Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
    Via ACCESSWIRE
    Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
    Via ACCESSWIRE
    Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
    Via ACCESSWIRE
    Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
    Via ACCESSWIRE
    Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
    Via ACCESSWIRE
    Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
    Via ACCESSWIRE
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    11 12 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.